Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study

被引：8

作者：

Elman, Lauren ^{[1
]}

Youn, Bora ^{[2
]}

Proud, Crystal M. ^{[3
]}

Frey, Margaret R. ^{[4
]}

Ajroud-Driss, Senda ^{[5
]}

McCormick, M. Eileen ^{[6
]}

Michelson, David ^{[7
]}

Cartwright, Michael S. ^{[8
]}

Heiman-Patterson, Terry ^{[9
]}

Choi, Joseph M. ^{[10
]}

Chandak, Aastha ^{[11
]}

Khachatryan, Artak ^{[12
]}

Martinez, Marta ^{[12
]}

Paradis, Angela D. ^{[2
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Biogen, Cambridge, MA USA

[3] Childrens Hosp Kings Daughters, Norfolk, VA USA

[4] Mem Healthcare Inst Neurosci, Owosso, MI USA

[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[6] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA

[7] Loma Linda Univ Hlth, Loma Linda, CA USA

[8] Wake Forest Sch Med, Winston Salem, NC 27101 USA

[9] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA

[10] Georgetown Univ Hosp, Washington, DC 20007 USA

[11] Certara, New York, NY USA

[12] Certara, London, England

来源：

JOURNAL OF NEUROMUSCULAR DISEASES | 2022年 / 9卷 / 05期

关键词：

Medication adherence; spinal muscular atrophy; antisense oligonucleotides; neuromuscular diseases; retrospective studies; adults; SHAM CONTROL;

D O I：

10.3233/JND-210768

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Limited evidence exists on real-world adherence to nusinersen for the treatment of spinal muscular atrophy (SMA). Data are presented from a multi-site retrospective chart review of 86 adults with SMA initiating nusinersen at nine US centers between January 2017 and February 2019. Seventy-nine (92%) adults remained on nusinersen during the study; 454 (92%) of 493 total nusinersen doses were received on time. Fifty-eight (67%) adults received all nusinersen doses on time. The majority of patients with at least one nonadherent dose resumed nusinersen on time. Most patients followed the dosing schedule across the loading and maintenance dose periods.

引用

页码：655 / 660

页数：6

共 50 条

[31] Efficacy of Nusinersen Treatment in Type 1, 2, and 3 Spinal Muscular Atrophy: Real-World Data from a Single-Center Study
Lemska, Anna
Ruminski, Piotr
Szymarek, Jakub
Studzinska, Sylwia
Mazurkiewicz-Beldzinska, Maria
NEUROLOGY INTERNATIONAL, 2024, 16 (06): : 1266 - 1278
[32] Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience
Mendonca, Rodrigo H.
Polido, Graziela J.
Matsui, Ciro
Silva, Andre M. S.
Solla, Davi J. F.
Reed, Umbertina C.
Zanoteli, Edmar
JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (01) : 101 - 108
[33] Prospective open-label study of Nusinersen treatment for adults with Spinal Muscular Atrophy
Elsheikh, Bakri
Severyn, Steven
Arnold, William
Kolb, Stephen
Kissel, John
NEUROLOGY, 2019, 92 (15)
[34] Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis
Hagenacker, Tim
Maggi, Lorenzo
Coratti, Giorgia
Youn, Bora
Raynaud, Stephanie
Paradis, Angela D.
Mercuri, Eugenio
NEUROLOGY AND THERAPY, 2024, 13 (05) : 1483 - 1504
[35] Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland
Krupa, Dominika
Czech, Marcin
Chudzynska, Ewa
Kon, Beata
Kostera-Pruszczyk, Anna
HEALTHCARE, 2023, 11 (10)
[36] Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China
Peng, Jing
Yao, Xiaoli
Luo, Rong
Wang, Xiuxia
Wu, Liwen
Zhong, Jianmin
Jin, Ruifeng
Lu, Xinguo
Liang, Jianmin
Hong, Siqi
Yang, Lin
Zhang, Xiaoli
Mao, Shanshan
Tao, Zhe
Hu, Jun
Sun, Dan
Wang, Hua
Zhang, Li
Xia, Yanyan
Chen, Ken
Wang, Yi
BMC PEDIATRICS, 2025, 25 (01)
[37] Real-world outcomes of onasemnogene abeparvovec (OA) alone or with prior nusinersen in pediatric SMA: Interim analysis of a US chart review
Dabbous, O.
Yang, M.
Georgieva, M.
Toro, W.
LaMarca, N.
Patel, A.
Minkoff, N.
Carley, C.
Zhu, J.
Anderson, A.
Wu, E.
NEUROMUSCULAR DISORDERS, 2021, 31 : S139 - S139
[38] Real-world data on the effectiveness and safety of onasemnogene abeparvovec in spinal muscular atrophy
Weiss, C.
Becker, L.
Garbade, S.
Johannsen, J.
Ziegler, A.
NEUROMUSCULAR DISORDERS, 2024, 43
[39] Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis
Gavriilaki, Maria
Moschou, Maria
Papaliagkas, Vasileios
Notas, Konstantinos
Chatzikyriakou, Evangelia
Papagiannopoulos, Sotirios
Arnaoutoglou, Marianthi
Kimiskidis, Vasilios K.
NEUROTHERAPEUTICS, 2022, 19 (02) : 464 - 475
[40] Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis
Maria Gavriilaki
Maria Moschou
Vasileios Papaliagkas
Konstantinos Notas
Evangelia Chatzikyriakou
Sotirios Papagiannopoulos
Marianthi Arnaoutoglou
Vasilios K. Kimiskidis
Neurotherapeutics, 2022, 19 : 464 - 475

← 1 2 3 4 5 →